CurrentCareSourcePolicy N/A

Molecular diagnostic testing (MDT) by PCR — Arkansas PASSE

Administrative policy governing use of molecular diagnostic testing (PCR-based MDT) for Arkansas PASSE members, specifying when MDT is medically necessary relative to conventional testing and provider documentation/coding requirements.

Policy Summary

PayerCareSource

PolicyMolecular diagnostic testing (MDT) by PCR — Arkansas PASSE

Policy CodePolicy N/A

Change TypeNo material change

Effective DateFeb 1, 2026

Next Review DateN/A

Key ActionOrder conventional testing first; MDT by PCR is medically necessary only if conventional testing is negative and symptoms support the diagnosis.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Conventional firstPreferred initial testing approach

Conventional negativeCondition for MDT coverage

Documentation may be requestedDocumentation audits possible

Highest specificityCoding requirement

Coverage Criteria for Molecular Diagnostic Testing (MDT) by PCR

MDT by PCR medical necessity logic

Covered when the following ordered logic is met:

Primary sequence

If conventional testing negative: MDT by PCR testing is medically necessary to confirm diagnosis if the member's presenting symptoms support the diagnosis.

Exception: Diseases complicating pregnancy are an exception to the requirement to use conventional testing first.

CareSource requires that conventional testing (for example, rapid antigen direct tests, direct fluorescent antibody testing, and cultures) be used as the preferred, lower-cost initial diagnostic approach before performing molecular diagnostic testing (MDT) by PCR. Providers should perform and document conventional test results prior to ordering PCR-based MDT except in recognized exceptions (see policy).

When conventional testing is positive, additional MDT by PCR is not medically necessary. PCR-based MDT is reserved for situations in which conventional testing is negative and the member's presenting symptoms support the diagnosis.

Policy Summary

PayerCareSource

PolicyMolecular diagnostic testing (MDT) by PCR — Arkansas PASSE

Policy CodePolicy N/A

Change TypeNo material change

Effective DateFeb 1, 2026

Next Review DateN/A

Key ActionOrder conventional testing first; MDT by PCR is medically necessary only if conventional testing is negative and symptoms support the diagnosis.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

When MDT by PCR May Be Covered

Confirmation of diagnosis when conventional testing is negative and presenting symptoms support the diagnosis.

Covered when ALL of the following are met:

Confirmation of diagnosis following negative conventional tests: Conventional testing (eg, rapid antigen, direct fluorescent antibody testing, cultures) has been performed and the result is negative.

Per policy, conventional testing should be utilized first.

Supporting clinical presentation: The member's presenting signs and symptoms are consistent with the suspected diagnosis and support confirmation by MDT by PCR.

PCR technical prerequisites: Appropriate molecular testing is available that targets the known gene sequence or target boundaries required for PCR amplification.

PCR requires knowledge of the gene sequence or borders of the target segment to be amplified; laboratory CLIA requirements apply.

Provider Responsibilities and Billing Requirements

Step Therapy

Step therapy preference for conventional testing

CareSource prefers lower-cost conventional diagnostic tests (for example, rapid antigen/direct tests, direct fluorescent antibody testing, and cultures) be used before multidisease testing (MDT) by PCR. Providers should perform conventional testing first; if conventional testing is positive, no further testing is medically necessary. If conventional testing is negative, MDT by PCR is medically necessary when the member's presenting symptoms support the diagnosis. Diseases complicating pregnancy are an exception to this step-therapy preference. CareSource may request documentation to support medical necessity.

Conventional testing (e.g., rapid antigen, direct fluorescent antibody, cultures) is preferred before MDT by PCR.
If conventional test result is positive — no further testing is medically necessary.
If conventional test result is negative and symptoms support the diagnosis — MDT by PCR is medically necessary.
Exception: diseases complicating pregnancy may bypass the step-therapy preference.
CareSource may request documentation to support medical necessity.

Denial Risk

Coding-related denials

Providers must code to the highest degree of specificity for CPT, HCPCS and diagnosis codes. Failing to use the most appropriate and highest-specificity codes may result in claim denials. CareSource may request supporting documentation; ensure documentation in the medical record justifies the selected codes and the medical necessity of testing performed.

Code to highest specificity for CPT, HCPCS, and ICD-10 diagnosis codes.
Use the most appropriate code(s) that reflect the service provided; generic or less-specific codes may lead to denials.
Maintain and provide documentation linking clinical findings and symptoms to the testing ordered when requested by CareSource.

Documentation Required

Documentation and coding

CareSource may request documentation to support medical necessity and to validate coding. Providers should be prepared to submit clinical notes, conventional test results, symptom documentation, and any other relevant records when requested. When submitting claims, ensure documentation supports any exception (for example, testing for diseases complicating pregnancy) and any use of MDT by PCR despite negative conventional testing.

Documentation may be requested to support medical necessity for MDT by PCR following negative conventional testing.
When exceptions are applied (e.g., diseases complicating pregnancy), include documentation explaining the rationale.
Ensure medical records substantiate the diagnosis, symptomatology, and testing pathway used.

Definitions

Molecular Diagnostic Testing (MDT) — definition

DefinitionLaboratory methods used to identify a disease or risk of developing a disease (eg, cancer) by studying molecules such as DNA, RNA, and proteins in a tissue or fluid sample

Clinical usesMay help plan treatment, detect recurrence, or monitor how well treatment is working

Common technique referencedOften uses PCR to amplify target sequences for detection

Polymerase Chain Reaction (PCR) — definition

DefinitionA laboratory method used to look for specific changes in a DNA sequence; can detect genetic conditions, diagnose disease, or identify DNA from bacteria, viruses, or other microorganisms

Technical requirementPCR amplifies target DNA and requires knowledge of the gene sequence or at minimum the borders of the target segment to be amplified

Relation to MDTPCR is the genetic amplification technique commonly utilized by molecular diagnostic testing to achieve faster processing times

OpenPayer

Molecular diagnostic testing (MDT) by PCR — Arkansas PASSE

Coverage Criteria for Molecular Diagnostic Testing (MDT) by PCR

When MDT by PCR May Be Covered

Coding and Technical Details

Provider Responsibilities and Billing Requirements

Ordering Requirements

Not Medically Necessary / Not Covered

Background

Definitions